Kailera Therapeutics, Inc. (KLRA) stock
KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$11.79−0.41 (-3.36%)
Close on Nov 18, 2026Market cap $1.53BP/E –Yield –
Kailera Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$133.67M | – |
| Q2 FY2026 | Jun 30, 2026 | -$77.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$68.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.20M | – |
See a number that looks wrong?